Overview

Trastuzumab Plus Taxane Neoadjuvant Therapy for HER2-Positive Breast Carcinoma: A Phase II Study

Status:
ENROLLING_BY_INVITATION

Trial end date:
2030-01-01

Target enrollment:

Participant gender:

Summary

This is a phase II single-center single-arm clinical study designed to analyze the efficacy and safety of trastuzumab combined with taxane neoadjuvant therapy for HER2-positive breast carcinoma in situ (or with invasive carcinoma).

Phase:

PHASE2

Details

Lead Sponsor:

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Collaborator:

Peking University Shenzhen Hospital